Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

ently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the protocol, design, scope, enrollment and other aspects of current and planned clinical trials and other studies of Arena's or its collaborators' product candidates and compounds; the future results of clinical trials; the tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; an NDA submission for lorcaserin and the potential partnering and commercialization of the drug candidate; expectations relating to the agreements and Arena's relationship with Siegfried; the advancement and content of Arena's pipeline; and other statements about Arena's outlook, strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receip
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Microban International, Ltd., the global ... partnered with Sharp Imaging and Information Company ... to incorporate it,s third generation silver-based antimicrobial ... into the calculator keys during manufacture, Microban ... of damaging bacteria on the keys. ...
(Date:12/10/2009)... -- Newly published research, by investigators, at ... (NESCI) in the journal STEM CELLS reported ... with "Limbal Stem Cell Deficiency" (LSCD) using ... need of suppressing their immunity. ,, ... a painful, blinding disease that requires long-term, ...
(Date:12/10/2009)... Vivakor, Inc. (OTC Bulletin Board: ... into an exclusive, $5 million license agreement ... ( www.regeneca.com ). The agreement exclusively ... new cutting-edge nutraceutical formulation developed by Vivakor ... formulations by Vivakor for Regeneca. Under the ...
(Date:12/10/2009)... SEATTLE, Dec. 10 Dendreon Corporation (Nasdaq: ... the Company as chief operating officer, effective January 4, ... of the specialty medicine business at Bayer, where he ... and neurology products. Mr. Bishop also served as ... ,, As a member of the Dendreon executive management ...
Breaking Biology Technology:Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3Dendreon Appoints Hans Bishop as Chief Operating Officer 2
... Promega Corporation, Madison, WI, USA , , ... , Rev. 07/2006 , ... Correlated measurement of an apoptosis marker (or caspase activity) , and cell ... one assay well , Assay miniaturization up to 1536-well format , ...
... , New Brunswick Scientific ... 30 seconds, making manual counting obsolete. Like the original NuceloCounter , ... yeast combines a fluorescence microscope with CCD camera and integrated image analysis ... , Monitoring ...
... Introduction , ... ® expression data. These statistical algorithms, created in ... typical distribution of data found in microarray experiments. The ... optimized to accommodate advancements in array and probe selection ...
Other Biology Technology:Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 2Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 3Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 4Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 5 New Automated Yeast Cell Counter Ends Tedium & Errors of Manual Counting 2New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays 2New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays 3New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays 4New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays 5New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays 6
(Date:12/14/2009)... December 10, 2009If you are spending the holidays with ... whether you would be better off with another family, ... , A research team from McMaster University and the ... cichlids, a species that lives in groups, members make ... results appear in the current issue of Biology ...
(Date:12/14/2009)... of the United Nations Framework Convention on Climate ... Agency hosted the ,Bend the Trend, event on ... platform and premiere the screening of the new ... of Europe, a joint project of the European ... and ESA, is a series of short films ...
(Date:12/13/2009)... that may help to engineer plants that take advantage ... The finding could help to engineer crops that take ... the carbon dioxide they need for photosynthesis through microscopic ... each molecule of the gas gained, they lose hundreds ... can tighten to save water when CO 2 ...
Breaking Biology News(10 mins):'Environmental Atlas of Europe' unveiled at COP15 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 1Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 2Western Governors University Nursing Education Program Receives 24500 000 Grant from the Texas Workforce Commission 48671 1Western Governors University Nursing Education Program Receives 24500 000 Grant from the Texas Workforce Commission 48671 2Western Governors University Nursing Education Program Receives 24500 000 Grant from the Texas Workforce Commission 48671 3Wyeth Declares Common Stock Dividend 12590 1
... technologies offer new opportunities to explore how genes ... challenge of analyzing huge amounts of genetic and ... the Lausanne Branch of the international Ludwig Institute ... Bioinformatics (SIB) and the University Hospital of Lausanne ...
... by mixing it with sugar, making thick jams that ... National Institute of Standards and Technology (NIST) have discovered* ... extend the life of many things including vaccines, food ... In addition to jams, sugars are often used to ...
... major asthma discovery by a researcher at the La ... by MedImmune, a leading innovation-focused biotechnology company and wholly ... discovery to explore its use in the development of ... , Under the agreement, MedImmune was granted exclusive ...
Other Biology News:New tool for genome-wide association studies 2Probing and controlling 'molecular rattling' may mean better preservatives 2La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 2La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 3
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: